Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (13734)	6/1/2000 9:20:00 AM
From: ballydog1	Read Replies (1) \| Respond to of 17367

Thanks Larry S. Read Scogale's review. Still stand by my previous post, wait for proper peer reviewed forum to publish data. As someone said (please enlighten me), "There's no stopping an idea whose time has come". Xoma's time just hasn't come yet (if ever). Politics is being held up as the big bugaboo to approval by the FDA. Maybe so, but I'm not convinced the data is anything (despite "compelling" being used by Castello) yet, except unconvincing. Seems like there's a serious conflict of interest for Xoma shareholders to be leading the charge to the FDA for an approval at this point, as it would or could be interpreted as being all about their personal financial gain. Unless & until disinterested third parties can be convinced of the benefit(s) of Neuprex, there will be no progress. Taking the summer off from Xoma, I remain.... the as yet unconvinced Ballydog1